SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVO.L Regulatory News (DVO)

  • There is currently no data for DVO

IMS & AGM

18 Apr 2013 07:00

RNS Number : 6284C
Devro PLC
18 April 2013
 



For immediate release 18 April 2013

 

 

Devro plc

(the "Group")

 

Interim Management Statement and Annual General Meeting

Devro plc, one of the world's leading manufacturers of collagen products for the food industry, today issues the following Interim Management Statement for the period from 1 January 2013 to date, ahead of its Annual General Meeting to be held at 11.00am. Steve Hannam, Chairman of Devro, will make the following statement on current trading.

 

"Devro's global sales have continued to grow during the period. This has been underpinned by good growth in much of Europe and North America, offset by a slower start in the UK and Australia. Select has begun the year well, particularly in Germany where it continues to make good progress.

 

"The major capital investment programme in the Czech Republic is proceeding as planned, with significant additional volume scheduled to come on stream in the second half of this year in order to support further growth in 2014.

 

"As announced at the time of the 2012 preliminary results, we have now implemented the planned price increases we referred to at that time. Input costs have also risen broadly in line with our expectations.

 

"Manufacturing performance, however, has been held back by lower yields, particularly in the USA, which has restricted product available for sale and impacted unit costs.

 

"We remain confident that the Group will meet the board's expectations for the full year. Whilst profits for the first quarter of the year are below the corresponding period in 2012 due to lower production yields, remedial action has already been taken and, with the benefits of recent price rises, additional volume from extra capacity and a focus on improving production processes, we do expect stronger performance as the year progresses.

 

"Net debt and cash flow are both as expected and the financial position of Devro continues to be strong."

 

Peter Page, Chief Executive, commented "Sales continue to grow in volume and value terms across the Group and our investments in people and infrastructure will ensure we have the necessary capability to take advantage of the significant opportunities that exist."

 

ENDS

 

For further information, please contact:

 

Devro plc

Peter Page, Chief Executive

Simon Webb, Group Finance Director

 

 

 

Tel No: 0207 182 4960

 

Buchanan

Diane Stewart/ Carrie Clement/

Charles Ryland

 

 

 

Tel No: 020 7466 5000/0131 226 6150

www.buchanan.uk.com

 

Notes to Editors

 

FTSE 250 listed Devro is one of the world's leading providers of collagen casings to the food industry supplying a wide range of products and technical support to manufacturers of sausages, salamis, hams and other cooked meats. The Group employs 2,200 staff across the world and produces its casings from 5 manufacturing sites based in Scotland, Australia, the Czech Republic and the USA. Devro reported sales of £241.1 million and profit before tax (excluding pension interest) of £42.2 million for the year ended 31 December 2012. Devro is a constituent of the FTSE4Good Index Series which recognises that the company's performance meets globally recognised corporate responsibility standards.

 

Further information on Devro can be found on the company's website: www.devro.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGUWUCUPWGBM
Date   Source Headline
7th Apr 20204:00 pmRNS2019 Annual Report and Notice of AGM
31st Mar 202012:03 pmRNSPrice Monitoring Extension
26th Mar 20204:37 pmRNSPrice Monitoring Extension
17th Mar 20207:00 amRNSDirectorate Changes
9th Mar 20202:26 pmRNSHolding(s) in Company
6th Mar 20205:10 pmRNSDirector/PDMR Shareholding
6th Mar 202012:11 pmRNSDirector/PDMR Shareholding
6th Mar 202012:11 pmRNSDirector/PDMR Shareholding
4th Mar 20207:00 amRNSFull Year Results
17th Jan 20207:00 amRNSTrading Update
12th Dec 20198:42 amRNSDirector Declaration
25th Oct 20195:31 pmRNSDirector/PDMR Shareholding
24th Oct 201910:57 amRNSDirector/PDMR Shareholding
22nd Oct 20197:00 amRNSTrading Update & Manufacturing Footprint Review
10th Oct 201911:44 amRNSDirector/PDMR Shareholding
20th Sep 201912:59 pmRNSHolding(s) in Company
14th Aug 20191:45 pmRNSHolding(s) in Company
31st Jul 20197:00 amRNSHALF YEAR RESULTS
5th Jul 20191:17 pmRNSHolding(s) in Company
19th Jun 20197:00 amRNSHolding(s) in Company
15th May 20196:24 pmRNSDirector/PDMR Shareholding
14th May 20193:44 pmRNSDirector/PDMR Shareholding
7th May 20197:00 amRNSDirectorate Changes
2nd May 20193:28 pmRNSDirector/PDMR Shareholding
25th Apr 20194:04 pmRNSResult of AGM
25th Apr 20197:00 amRNSTrading Update
12th Apr 20191:08 pmRNSCompany Secretary change
11th Apr 201910:48 amRNSDirector/PDMR Shareholding
22nd Mar 20194:07 pmRNS2018 Annual Report and Notice of AGM
19th Mar 20192:00 pmRNSCapital Markets Event
6th Mar 20192:09 pmRNSDirector/PDMR Shareholding
6th Mar 20192:08 pmRNSDirector/PDMR Shareholding
26th Feb 20197:00 amRNSFull Year Results
20th Feb 20193:27 pmRNSHolding(s) in Company
14th Feb 201911:59 amRNSHolding(s) in Company
14th Feb 201911:34 amRNSDirector/PDMR Shareholding
23rd Jan 20193:02 pmRNSHolding(s) in Company
10th Dec 20184:05 pmRNSHolding(s) in Company
4th Dec 20184:46 pmRNSHolding(s) in Company
20th Nov 20183:33 pmRNSHolding(s) in Company
20th Nov 201811:51 amRNSHolding(s) in Company
19th Nov 20181:35 pmRNSDirector/PDMR Shareholding
19th Nov 20181:34 pmRNSDirector/PDMR Shareholding
16th Nov 201810:33 amRNSDirector/PDMR Shareholding
15th Nov 20187:00 amRNSRetirement of Chairman
15th Nov 20187:00 amRNSTrading Update
5th Nov 20181:49 pmRNSHolding(s) in Company
23rd Oct 20183:47 pmRNSHolding(s) in Company
15th Oct 20184:27 pmRNSDirector/PDMR Shareholding
18th Sep 201811:33 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.